Cagrilintide B5mg + Semaglutide 10mg Research Peptide: A Dual‑Mechanism Combination for Metabolic & Obesity Studies

If your research explores complementary pathways in appetite regulation, energy balance, and glycaemic control, the Cagrilintide B5mg + Semaglutide 10mg research peptide offers a precisely formulated, dual‑mechanism experimental platform. This fixed‑dose combination, known in clinical research as CagriSema, unites two well‑characterised peptide therapeutics with distinct yet complementary modes of action. Cagrilintide is a long‑acting amylin and calcitonin receptor agonist (a DACRA) that induces satiety through brainstem pathways, while semaglutide is a potent GLP‑1 receptor agonist that reduces food intake and improves glycaemic control Cagrilintide B5mg + Semaglutide 10mg .

By targeting both the amylin/calcitonin system and the incretin pathway, this combination allows researchers to model the synergistic interplay that governs appetite suppression and metabolic regulation, providing deeper insight into the regulatory circuits that drive weight loss and glycaemic improvement.

At Wuhan Top Miracle Peptides, we supply high‑purity Cagrilintide B5mg + Semaglutide 10mg research peptide to research institutions and wholesale buyers across the United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA. Every batch is lyophilised, HPLC‑verified to ≥98% purity, and accompanied by a Certificate of Analysis (COA), ensuring your investigations into metabolic regulation, satiety signalling, and obesity research begin with uncompromising quality.

What Is the Cagrilintide B5mg + Semaglutide 10mg Combination and How Does It Work?

To fully appreciate the research potential of the Cagrilintide B5mg + Semaglutide 10mg research peptide, it is essential to understand the distinct yet complementary mechanisms of its two components.

Cagrilintide: The Dual Amylin & Calcitonin Receptor Agonist (DACRA)

Cagrilintide (AM833) is a long‑acting, lipidated analogue of the pancreatic hormone amylin. It is engineered as a dual amylin and calcitonin receptor agonist (DACRA), binding non‑selectively to amylin receptors (AMY1R, AMY2R, AMY3R) and the calcitonin receptor (CTR). Cryo‑EM structural studies reveal that cagrilintide adopts a distinct “bypass” binding mode, anchored at the receptor transmembrane bundle level by key residues including F23Cagri.

Mechanism of Action: Cagrilintide activates Gs‑coupled signalling pathways through both CTR and AMY1R, increasing intracellular cAMP. It exerts its effects on energy balance through the dorsal vagal complex (DVC) of the brainstem, where long‑term treatment upregulates prolactin‑releasing hormone (Prlh) expression in Calcr/Prlh neurons. This neural pathway mediates satiety and reduces food intake. In preclinical studies, cagrilintide induces 11.8% weight loss over 68 weeks as monotherapy.

Semaglutide: The GLP‑1 Receptor Agonist

Semaglutide is a well‑established GLP‑1 receptor agonist with proven weight‑loss and cardiovascular benefits at a dose of 2.4 mg. It reduces appetite, delays gastric emptying, and improves glycaemic control through GLP‑1 receptor activation.

Mechanism of Synergy: Dual‑Pathway Satiety Signalling

The scientific rationale for combining cagrilintide and semaglutide lies in their convergent yet distinct mechanisms:

• Cagrilintide targets the amylin/calcitonin system, activating brainstem pathways that induce satiety and reduce food intake through a non‑incretin mechanism.

• Semaglutide targets the GLP‑1 system, reducing appetite, improving glycaemic control, and promoting weight loss through well‑characterised incretin pathways.

• Distinct Mechanisms: CagriSema reduces energy intake and appetite without significantly delaying gastric emptying, suggesting that the two components work through complementary rather than redundant pathways.

• Greater Efficacy: In the phase 3 REDEFINE 1 trial (3417 participants without diabetes), CagriSema (2.4 mg each) achieved a 20.4% mean weight loss at week 68 compared to 3.0% with placebo — an estimated difference of 17.3 percentage points. In the REDEFINE 2 trial (1206 participants with type 2 diabetes), CagriSema resulted in 13.7% weight loss compared to 3.4% with placebo.

Key Research Applications for Cagrilintide + Semaglutide

The Cagrilintide B5mg + Semaglutide 10mg research peptide is a versatile tool with applications spanning several domains of biomedical research.

1. Obesity & Metabolic Research

As a dual‑mechanism combination that induces significant weight loss through satiety signalling, this blend is a valuable tool for studying obesity pathophysiology. Research applications include:

• Satiety Signalling Pathways: Investigating the neural circuits and molecular mechanisms through which amylin receptor and GLP‑1 receptor activation synergistically reduce food intake.

• Energy Balance Studies: Exploring how the combination modulates energy expenditure, metabolic rate, and fat mass reduction.

• Dose‑Response Studies: Characterising the dose‑dependent effects of varying cagrilintide and semaglutide ratios on food intake, body weight, and metabolic parameters.

• Adipose Tissue Research: Studying the effects of the combination on fat mass distribution and adipocyte function.

2. Type 2 Diabetes & Glycaemic Control Research

CagriSema has demonstrated superior glycaemic outcomes across multiple phase 3 trials. Research applications include:

• HbA1c Reduction Studies: In REIMAGINE 2 (2728 participants with type 2 diabetes), CagriSema (2.4 mg/2.4 mg) achieved 1.91% HbA1c reduction from a baseline of 8.2%, compared to 1.76% with semaglutide 2.4 mg.

• Glycaemic Control: 73.5% of patients in the CagriSema group achieved HbA1c levels of 6.5% or less, compared to 15.9% in the placebo group.

• Metabolic Syndrome Research: Studying the combination’s effects on multiple metabolic parameters including glucose, lipids, and blood pressure.

3. Receptor Pharmacology & Signalling Research

As a combination of two mechanistically distinct receptor agonists, this blend serves as a molecular probe for studying receptor pharmacology:

• Receptor Binding Studies: Characterising the binding affinity and selectivity of cagrilintide for AMYRs and CTR, and semaglutide for GLP‑1R.

• Signal Transduction Studies: Dissecting the Gs‑protein signalling pathways activated by dual receptor engagement.

• Structural Studies: Using cagrilintide and semaglutide as tools to elucidate receptor complex structures.

4. Neuroscience & Brain‑Gut Axis Research

Cagrilintide’s effects on the dorsal vagal complex make this combination a valuable tool for studying the neural control of feeding:

• Brainstem Circuitry: Investigating how amylin receptor activation modulates neuronal populations in the area postrema and nucleus of the solitary tract.

• Prlh Signalling: Studying the role of prolactin‑releasing hormone in mediating the effects of amylin receptor agonists.

• Cross‑Species Conservation: Exploring conserved neural mechanisms of energy balance regulation across species.

5. Combination & Add‑On Therapy Research

The CagriSema combination has been investigated across multiple clinical contexts:

• Add‑On to Basal Insulin: REIMAGINE 3 is investigating CagriSema as an add‑on to basal insulin in adults with type 2 diabetes.

• East Asian Populations: REDEFINE 5 is assessing the fixed‑dose combination in east Asian populations.

• Long‑Term Weight Management: The REDEFINE 8 trial is evaluating long‑term weight management benefits of CagriSema in people with obesity.

Chemical & Physical Specifications for Cagrilintide B5mg + Semaglutide 10mg

Accurate characterisation of the Cagrilintide B5mg + Semaglutide 10mg research peptide is essential for reproducible experimental design.

Note: The 5 mg and 10 mg masses refer to the weight of each component in its lyophilised form. The blend is supplied as a fixed‑dose combination in a single lyophilised vial. This ratio reflects the clinical research formulation of CagriSema (2.4 mg cagrilintide + 2.4 mg semaglutide in the 1:1 ratio, scaled proportionally for research purposes). For research use only. Not for human use.

Reconstitution & Handling Protocol for Cagrilintide + Semaglutide

Proper reconstitution of the Cagrilintide B5mg + Semaglutide 10mg research peptide is critical for maintaining the structural integrity and biological activity of both components.

Step 1 – Preparation

• Bring the sealed blend vial and your chosen diluent (sterile bacteriostatic water or sterile PBS, pH 5‑7) to room temperature. Condensation can degrade the lyophilised powder.

• Clean your work surface with 70% ethanol and lay out sterile syringes, alcohol wipes and a clean work mat.

Step 2 – Vial Sanitisation

• Wipe the rubber stopper of the blend vial with a fresh 70% ethanol wipe. Allow the alcohol to evaporate completely before piercing.

Step 3 – Reconstitution

• Draw your desired volume of diluent into a sterile syringe. A common starting concentration for research applications is 15 mg per 1.5 mL of diluent, yielding a 10 mg/mL total peptide concentration.

• Insert the needle and slowly inject the diluent against the inner glass wall. Do not spray directly onto the lyophilised powder.

• Gently swirl the vial until the solution is clear and fully dissolved. Do not shake vigorously, as shaking can cause denaturation.

Step 4 – Aliquoting & Storage

• Immediately after dissolution, aliquot the reconstituted peptide blend into single‑use sterile vials.

• Store aliquots at –20°C for up to 1 month or at –80°C for up to 6 months.

• Avoid repeated freeze‑thaw cycles, as peptides are susceptible to degradation.

• Once thawed, store at 2‑8°C and use within a short period.

Concentration Reference Table for Cagrilintide B5mg + Semaglutide 10mg

Adjust diluent volume based on your experimental requirements. The exact concentration of each individual peptide within the blend is 5 mg cagrilintide and 10 mg semaglutide per 15 mg vial.

Storage & Stability Guidelines for Cagrilintide B5mg + Semaglutide 10mg

Why Choose Wuhan Top Miracle Peptides for Cagrilintide B5mg + Semaglutide 10mg

As an authentic licensed peptide supplier based in the United Kingdom, we supply the Cagrilintide B5mg + Semaglutide 10mg research peptide and a wide range of research‑grade compounds under rigorous quality assurance protocols, fully aligned with Google’s E‑E‑A‑T standards (Experience, Expertise, Authoritativeness, Trustworthiness).

• Verified Purity: Independent HPLC analysis with purity guaranteed ≥98% for each component, every batch.

• GMP‑Compliant Manufacturing: All peptides are synthesised under strict quality control conditions.

• Full Traceability: Batch‑specific Certificates of Analysis (COA) are available for every order.

• Wholesale Supply: We serve research institutions, laboratories, and wholesale buyers across the UK, EU, and USA with flexible volume pricing and reliable logistics.

• UK‑Based Regulatory Compliance: All products are supplied strictly as research‑grade chemicals for laboratory use only (RUO).

Researchers across the United Kingdom—including those at leading institutions in London, Cambridge, Oxford, Manchester, and Edinburgh—trust us for fast domestic delivery, transparent documentation and professional technical support.

FAQ: Cagrilintide B5mg + Semaglutide 10mg Research Peptide

What is the Cagrilintide B5mg + Semaglutide 10mg research peptide?
It is a research‑grade, fixed‑dose combination of cagrilintide (a dual amylin and calcitonin receptor agonist) and semaglutide (a GLP‑1 receptor agonist). Known clinically as CagriSema, it is used as a dual‑pathway tool to study appetite suppression, energy balance, glycaemic control, and obesity.

How does each component work?
Cagrilintide binds to amylin receptors (AMY1R, AMY2R, AMY3R) and the calcitonin receptor (CTR), activating Gs‑signalling pathways that induce satiety through brainstem pathways. Semaglutide activates GLP‑1 receptors, reducing appetite, delaying gastric emptying, and improving glycaemic control.

What is the proposed synergy between cagrilintide and semaglutide?
Cagrilintide targets the amylin/calcitonin system through non‑incretin pathways, while semaglutide targets the GLP‑1 system. Together, they reduce energy intake and appetite through complementary mechanisms. Clinical trials have demonstrated significantly greater weight loss and glycaemic control with the combination compared to either component alone.

What are the primary research applications for this blend?
The blend is used in obesity and metabolic research, type 2 diabetes and glycaemic control studies, receptor pharmacology and signalling research, neuroscience and brain‑gut axis research, and combination/add‑on therapy research.

What clinical trial data support the CagriSema combination?
In the phase 3 REDEFINE 1 trial, CagriSema achieved 20.4% mean weight loss versus 3.0% with placebo in 3417 adults without diabetes. In the REDEFINE 2 trial, it achieved 13.7% weight loss versus 3.4% with placebo in 1206 adults with type 2 diabetes. In REIMAGINE 2, CagriSema demonstrated 1.91% HbA1c reduction and 14.2% weight loss.

What purity does your Cagrilintide + Semaglutide blend meet?
Each component is tested to ≥98% purity by HPLC. A Certificate of Analysis (COA) is supplied with every order.

How should I reconstitute this peptide blend?
Reconstitute with sterile bacteriostatic water or sterile PBS (pH 5‑7). Allow the vial to reach room temperature, then slowly inject the diluent against the inner glass wall and swirl gently. Do not shake.

How should I store reconstituted peptide blends?
Reconstituted blends should be stored at –20°C for up to 1 month or at –80°C for up to 6 months. Aliquot immediately into single‑use vials and avoid repeated freeze‑thaw cycles.

Is this peptide blend legal to purchase in the UK for research?
Yes. This blend is a laboratory reagent sold for research use only (RUO). It is fully legal to purchase, possess, and use in the United Kingdom for legitimate in‑vitro or in‑vivo scientific research, provided it is not marketed with therapeutic claims. Note: CagriSema is an investigational compound currently under FDA review following a New Drug Application submission in December 2025 and is not yet approved for therapeutic use.

Does Wuhan Top Miracle Peptides ship internationally?
Yes. We ship across the EU (France, Germany, Spain, Sweden, Italy) and to the USA from our UK warehouse. Wholesale pricing is available for bulk orders.

Wholesale Cagrilintide B5mg + Semaglutide 10mg Blend Supply Across the UK and Europe

Wuhan Top Miracle Peptides supports wholesale peptide blend buyers in the United Kingdom and international markets.

We Support Enquiries From:

• United Kingdom
• France
• Germany
• Spain
• Sweden
• Italy
• USA
• Wider Europe

For larger Cagrilintide B5mg + Semaglutide 10mg Blend enquiries, contact our team before ordering. This helps confirm stock, documentation, shipping options, component identity, blend ratio, strength options, and buyer verification requirements.

Where to Source Cagrilintide B5mg + Semaglutide 10mg Blend in the UK

If you are searching for where to source Cagrilintide B5mg + Semaglutide 10mg Blend UK, Wuhan Top Miracle Peptides provides a simple professional enquiry process.

Professional Enquiry Process

1. Review the blend product details.
2. Check the current label and batch information.
3. Confirm whether the label says Cagrilintide 5mg or “B5mg.”
4. Confirm whether Semaglutide is listed as 10mg.
5. Ask about the total vial content and blend ratio.
6. Ask about COA and purity-related documentation.
7. Confirm sequence and salt form for each component where required.
8. Confirm storage conditions and shipping country.
9. Discuss wholesale quantity requirements.
10. Complete buyer verification where required.
11. Place a professional enquiry with support from our team.

Cagrilintide B5mg + Semaglutide 10mg

Bulk Peptides Page
Shipping & Returns Page
Contact Us Page
Shop Page
Quality / Compliance Page
Cagrilintide Product Page
Semaglutide Product Page
GLP-1 Research Category Page
Scientific or compound reference source
Official UK medicine advertising guidance
Google Search Central
ASA / CAP Code Section 12

Cagrilintide B5mg + Semaglutide 10mg

From its innovative design as a fixed‑dose combination of two mechanistically distinct receptor agonists to its well‑documented role in modelling the synergistic interplay between the amylin/calcitonin system and the GLP‑1 pathway, the Cagrilintide B5mg + Semaglutide 10mg research peptide provides a uniquely versatile platform for advanced metabolic and obesity research.

Its ability to induce significant weight loss and improve glycaemic control through complementary pathways—supported by large‑scale phase 3 clinical trials published in the New England Journal of Medicine, The Lancet, and other authoritative journals—makes it a valuable addition to any laboratory investigating appetite regulation, energy balance, obesity pathophysiology, or type 2 diabetes. By choosing high‑purity, lab‑verified Cagrilintide B5mg + Semaglutide 10mg research peptide from Wuhan Top Miracle Peptides, you ensure that your research is built on a foundation of quality, reproducibility, and scientific integrity.

Ready to advance your research with the Cagrilintide B5mg + Semaglutide 10mg blend? Browse our product catalogue, request a wholesale quote, or contact our support team today to discuss your laboratory’s specific needs. Place your order now and receive GMP‑grade research peptides delivered directly to your facility in the UK, EU, or USA.